TLDR
- KALA BIO revealed plans to release its inaugural commercial AI agent within roughly two weeks
- The firm aims to become the “Palantir for biotech” in a $180 billion AI healthcare market opportunity
- Researgency.ai will deliver AI-powered agents for pharmaceutical and biotech operations
- Shares jumped 69.68% in Wednesday’s pre-market session after gaining 12.82% on Tuesday
- Daily trading volume reached 51 million shares versus a three-month average of approximately 1.94 million
Shares of KALA BIO rocketed higher in Wednesday’s pre-market session following the clinical-stage biotechnology firm’s disclosure that it intends to release its inaugural commercial AI solution within approximately two weeks.
The revelation drove shares up 69.68% before the opening bell, building on Tuesday’s 12.82% advance. Trading activity surged past 51 million shares, dramatically exceeding the three-month daily average of around 1.94 million.
$KALA < $.50c – Kala Bio
🔹Launches a Revolution for Biotech
🔹First AI Agent Deploying in 14 Days
🔹Platform rebrand complete and https://t.co/u7uaqZThkx reported live for enterprise deployment
🔹Company retains a drug pipeline with Orphan Drug and Fast Track designations… pic.twitter.com/XqCPhrULlS— John Zidar aka/ Stock Wizard (@JohnZidar) March 11, 2026
The biotechnology company unveiled Researgency.ai, a specialized platform engineered to deliver AI-powered agents for pharmaceutical and biotechnology enterprises. KALA positions itself as the “Palantir for biotech,” referencing Palantir’s market valuation exceeding $250 billion as an aspirational benchmark.
CEO Avi Minkowitz of KALA stated directly: “Our first agent ships in 14 days, and our team is fired up.”
The organization is collaborating with Younet’s AI engineering division to develop the inaugural custom agent, scheduled for deployment by the end of March. The Researgency.ai platform has already gone live for enterprise customers.
Platform Capabilities Explained
These AI agents target labor-intensive, critical workflows throughout the drug development lifecycle. Key applications include research surveillance, clinical trial documentation management, regulatory compliance oversight, safety report generation, and commercial launch preparation.
According to KALA, these agents deliver superior speed, cost efficiency, and accuracy compared to human performance on similar tasks. The technology operates within a secure infrastructure engineered to satisfy pharmaceutical industry compliance requirements.
The company referenced market forecasts indicating the worldwide AI healthcare sector will surpass $180 billion by 2030. KALA’s current market capitalization stands at merely $8.3 million, with shares trading around $0.29.
Year-to-date, the stock has declined 47.21%, and it’s down 95.78% over the trailing twelve months. Even with Wednesday’s pre-market surge, shares remain trading near all-time lows.
Parallel Business Model and Financial Challenges
KALA BIO maintains a dual-pronged approach. The company continues advancing its biologics development pipeline, featuring FDA Orphan Drug and Fast Track designated therapeutic candidates derived from its mesenchymal stem cell secretome technology platform.
The strategic shift toward AI arrives amid significant financial headwinds. The company’s current ratio of 0.75 indicates that near-term liabilities surpass available liquid resources.
In recent months, KALA reached a settlement agreement with Oxford Finance regarding outstanding debt. The arrangement involved a $2 million payment to resolve approximately $10.6 million in liabilities stemming from an earlier financing agreement.
Additionally, the company recently ended its relationship with auditing firm Deloitte & Touche LLP. A successor auditor has not yet been announced.
KALA has not yet revealed pricing structures for the Researgency.ai platform, identified which specific workflow the first agent will address, or shared information regarding confirmed customer contracts.
Management indicated that comprehensive details about the inaugural agent will be disclosed following launch, including the targeted workflow area and performance metrics.
